Limb Girdle Muscular Dystrophy

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

AskBio
AskBioNC - Durham
1 program
1
AB-1003 dose level 1Phase 1/21 trial
Active Trials
NCT05230459Recruiting10Est. Dec 2032

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
2029
2030
2031
AskBioAB-1003 dose level 1

Clinical Trials (1)

Total enrollment: 10 patients across 1 trials

NCT05230459AskBioAB-1003 dose level 1

A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)

Start: May 2023Est. completion: Dec 203210 patients
Phase 1/2Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 10 patients
1 companies competing in this space